Kestra Medical Technologies (NASDAQ:KMTS) reported what management described as a strong third quarter of fiscal 2026, highlighted by higher prescriptions, accelerating revenue growth, and continued g ...

HeartFlow delivered 40% sales growth in 2025, with revenue surpassing $176 million and strong Q4 momentum. Learn more about HTFL stock here.

Good afternoon, everyone, and thank you for joining us today. 2025 was a year of exceptional execution, one that proved the strength of our business as we continue to build a world-leading financial ...

KESTRA MEDICAL TECHNOLOGIES, LTD. (NASDAQ:KMTS) Q3 2026 Earnings Call Transcript March 17, 2026 KESTRA MEDICAL TECHNOLOGIES, LTD. misses on earnings expectations. Reported EPS is $-0.61 EPS, ...

Enhanced Subgroup Performance: In the subgroup of patients with positive ECG-ML results, the investigation identified any ...

Planning a trip to Thailand? Here are the most common reasons travellers are denied entry and how to avoid them.

Ad fraud is no longer a fringe issue. It is a systemic threat to digital advertising, and its scale demands a technological ...

All animal studies were performed according to protocols approved by the University Committee on Animal Resources at the University of Rochester Medical ...